Summit Therapeutics Presents at Life Sciences Conference

Company discusses pipeline asset ivonescimab and global expansion plans.

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Summit Therapeutics, a biopharmaceutical company, presented at the Citizens Life Sciences Conference in Miami, Florida. Dave Gancarz, Chief Business & Strategy Officer, and Allen Yang, Chief Medical Officer, provided an overview of the company's main pipeline asset, ivonescimab, and its global expansion plans through a strategic partnership with Akeso Bio.

Why it matters

As a biotech company with a promising drug candidate, Summit Therapeutics' presentation at a major life sciences conference highlights the progress and potential of its pipeline. The details shared about the ivonescimab program and the company's global licensing deal provide insights into its growth strategy and competitive positioning in the pharmaceutical industry.

The details

Summit Therapeutics entered into a strategic partnership with Akeso Bio in December 2022 to develop and commercialize ivonescimab, its main pipeline asset, in major markets outside of China and Korea. The company has the rights to ivonescimab in North America, South America, Europe, Africa, the Middle East, and Japan. The partnership was motivated by encouraging Phase II data for ivonescimab, prompting Summit to quickly advance the drug candidate into late-stage clinical studies.

  • The strategic partnership with Akeso Bio went effective in January 2023.
  • Summit Therapeutics presented at the Citizens Life Sciences Conference on March 11, 2026.

The players

Summit Therapeutics Inc.

A biopharmaceutical company focused on developing its main pipeline asset, ivonescimab.

Akeso Bio

A Chinese biopharmaceutical company that partnered with Summit Therapeutics to develop and commercialize ivonescimab in China and Korea.

Dave Gancarz

Chief Business & Strategy Officer at Summit Therapeutics.

Allen Yang

Chief Medical Officer at Summit Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We entered into a strategic partnership with Akeso Bio in December of 2022. That deal went effective in January 2023 for ivonescimab. So Summit Therapeutics has the rights to ivonescimab in North America, South America, Europe, Africa, the Middle East and Japan.”

— Dave Gancarz, Chief Business & Strategy Officer

What’s next

Summit Therapeutics plans to quickly advance ivonescimab into late-stage clinical studies following the strategic partnership with Akeso Bio.

The takeaway

Summit Therapeutics' presentation at the Citizens Life Sciences Conference highlights the company's progress in developing its main pipeline asset, ivonescimab, and its global expansion strategy through a partnership with Akeso Bio. The details shared provide insights into the company's growth plans and competitive positioning in the pharmaceutical industry.